Centinel Spine announces first commercial use of prodisc C SK cervical total disc replacement device

5900
prodisc C SK cervical total disc replacement device (Centinel Spine)

Centinel Spine has announced the first implantation of its prodisc C SK cervical total disc replacement (TDR) product. In July 2022, the company received US Food and Drug Administration (FDA) approval for one-level indications for prodisc C Vivo, prodisc C SK, and prodisc C Nova.

Centinel Spine CEO, Steve Murray, said: “In spine care, each patient’s circumstances are different, so it is critical to provide surgeons with the ability to address each patient’s unique needs.

“With the release of both the prodisc C Vivo and prodisc C SK devices, we have expanded the options available to surgeons to allow for better matching of the disc to the patient. While these two new product releases have been conducted on a limited scale, we have already seen a strong positive response from surgeon partners related to the potential patient benefits.”

The prodisc C SK device features a flat endplate design for optimised implant positioning that allows surgeons to address individual patient anatomy—and a low-profile central keel that provides immediate fixation and enables a streamlined keel preparation technique, say Centinel Spine. Similar to all prodisc products, the prodisc C SK device incorporates prodisc CORE technology.

Ehsan Jazini, an orthopaedic surgeon at the Virginia Spine Institute (Reston, USA), added: “I am proud to be the first surgeon to use this innovative technology in the DC metro region. As a pioneer working to make disc replacement surgery ultra-customised for each patient, the prodisc C SK and prodisc C Vivo devices provide me the versatility to match the disc to the patient’s anatomy. With this advanced proven technology, we can best gain motion preservation and stability as appropriate for each cervical surgery.”

Orthopaedic spine surgeon, Jason Tinley, founder of the DFW Center for Spinal Disorders (Dallas-Fort Worth, USA), added: “With prodisc C SK now FDA-approved along with prodisc C Vivo and the original prodisc C, I have the intraoperative modularity to change implant characteristics based on patient morphology.

“While an MRI or X-ray may appear to favour the need for a flat endplate and keels versus a superior dome shape with spikes, once your carpentry is performed, I’ve found that it’s not uncommon that the alternative option may actually offer better stability and endplate conformity upon trialling.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here